Rethinking how we diagnose and treat postmenopausal osteoporosis with zoledronate and anabolics
A major Endocrine Reviews update argues for risk-based diagnosis and a lifelong treatment sequence, with infrequent zoledronate and anabolics for high-risk women.
Zusammenfassung
This narrative review from Reid and Bolland updates the management of postmenopausal osteoporosis. It argues that osteoporosis should be diagnosed by fracture risk rather than a bone density T-score below -2.5, since about 80% of women who fracture do not meet that cutoff. Lifestyle measures matter: healthy weight, safe exercise, no smoking, moderate alcohol, and falls prevention. Vitamin D helps mainly when levels fall below about 25-30 nmol/L, while high doses may harm. Bisphosphonates remain first-line, and zoledronate offers long-lasting protection from infrequent dosing. Denosumab works but needs an exit plan because its effect fades quickly. Anabolic drugs, including teriparatide, abaloparatide and romosozumab, are used first for 1-2 years in very high-risk patients, then followed by antiresorptives. The authors stress lifelong, sequenced treatment.
Detaillierte Zusammenfassung
Osteoporotic fractures are a growing public health burden as populations live longer. After menopause, falling estrogen accelerates bone turnover and bone loss, and fracture risk climbs steeply with age: in one US cohort, from 8 per 1000 patient-years at ages 50-54 to 31 per 1000 at ages 80-84. This review by Reid and Bolland summarizes current thinking on diagnosis, risk estimation and treatment.
The authors argue that the BMD-based definition (T-score below -2.5) is outdated. About 80% of postmenopausal women who fracture do not meet it, and the mismatch may reduce treatment uptake. They suggest diagnosing osteoporosis using the 1993 qualitative definition, with increased fracture susceptibility judged by calculated risk (FRAX, Garvan, Q-Fracture). They note that FRAX adjusts for competing mortality and can understate short-term benefit in older adults, and they support retaining ethnicity-specific models. Treatment thresholds suggested include a 10-year major osteoporotic fracture risk above 10-15% for antiresorptives and above 20-30% for anabolics.
Lifestyle measures include avoiding underweight (hip fracture risk rises sharply at BMI below 20), weight-bearing exercise, not smoking, limiting alcohol, and multifaceted falls prevention. Calcium intake has little clinical effect on fractures. Most large vitamin D trials were neutral. Benefit appears confined to people with 25-hydroxyvitamin D below about 25-30 nmol/L, for whom 400-1000 IU/day usually suffices, whereas doses above 2000 IU/day have been linked to bone loss, falls and fractures in some studies.
Oral bisphosphonates (alendronate, risedronate) cut hip fracture by about 40%, but absorption is about 1% and gastrointestinal intolerance is common. Alendronate's effects persist longer after stopping than risedronate's, supporting drug holidays. Zoledronate is the most potent and long-acting: in a 7736-woman trial it reduced vertebral fractures 70%, nonvertebral 25% and hip fractures 41%. In patients after hip fracture it reduced new clinical fractures 35% and mortality 28%. After 6 annual doses, BMD fell under 1% over 3 years off drug, and a post hoc analysis suggested a single dose may give benefit for about 3 years. Denosumab prevents fractures but needs strict 6-monthly dosing and a transition, usually to a bisphosphonate, because of rapid offset. PTH1-receptor anabolics raise spine BMD substantially but are not proven to prevent hip fractures, while romosozumab, an anti-sclerostin antibody, has both anabolic and antiresorptive effects and broad antifracture efficacy.
Overall, management should be lifelong and sequenced: anabolic first for the highest-risk patients, then antiresorptives. Optimal sequences and dosing intervals still need trials. The provided text was truncated, so later sections (osteopenia data, safety of ONJ/AFF, anabolic details) are not fully covered here.
Wichtigste Erkenntnisse
- About 80% of postmenopausal women who fracture have T-scores above -2.5, so BMD-only diagnosis misses most fracture-prone women.
- Vitamin D supplements help mainly when 25-hydroxyvitamin D is below about 25-30 nmol/L; doses above 2000 IU/day may increase falls and fractures.
- Zoledronate 5 mg annually cut vertebral fractures 70% and hip fractures 41% over 3 years, with BMD benefits persisting after 6 doses.
- Alendronate and risedronate reduce hip fracture about 40%; alendronate's effect persists longer after stopping, supporting drug holidays.
- High-risk patients typically receive an anabolic agent for 1-2 years, followed by long-term antiresorptive therapy to preserve gains.
Methodik
This is a narrative expert review in Endocrine Reviews, not a systematic review or new study. It synthesizes randomized trials, network meta-analyses, observational cohorts and guidelines on fracture risk estimation, lifestyle measures, vitamin D, and antiresorptive and anabolic drugs. The authors also offer opinion on diagnostic definitions and treatment frameworks.
Studienlimitierungen
As a narrative review, it is subject to selection bias, and some recommendations (such as risk-based diagnosis, dosing intervals and treatment sequences) reflect expert opinion with limited head-to-head fracture data. The available text was truncated, so detailed discussions of zoledronate in osteopenia, ONJ/AFF risk, and anabolic agents were not fully assessed. Anabolics lack proven hip fracture benefit, and optimal sequencing remains uncertain.
Hat dir diese Zusammenfassung gefallen?
Erhalte die neueste Longevity-Forschung jede Woche in deinen Posteingang.
E-Mail-Adresse zum Abonnieren eingeben: